Novo’s New Obesity Drug Seeks Groundbreaking Weight Loss Success
Novo Nordisk’s appetite-blocking shot semaglutide, sold under brand names Ozempic and Wegovy, is facing intense competition in the growing obesity market. The company hopes its new lead drug, CagriSema, will achieve at least 25% weight loss without increased side effects. CagriSema competes with Eli Lilly’s Zepbound (Mounjaro), which has shown similar or even greater weight … Read more